Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.10.5615

Prognostic Involvement of Nucleophosmin Mutations in Acute Myeloid Leaukemia  

Shahab, Sadaf (Molecular Biology, Pure and Applied Research, National Institute Blood Diseases and Bone Marrow Transplantation)
Shamsi, Tahir Sultan (Department of Haematology, National Institute Blood Diseases and Bone Marrow Transplantation)
Ahmed, Nuzhat (Molecular Biology, Pure and Applied Research, National Institute Blood Diseases and Bone Marrow Transplantation)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.10, 2013 , pp. 5615-5620 More about this Journal
Abstract
Nucleophosmin (NPM1) is a protein of highly conserved nature which works as a molecular chaperone and is mostly found in nucleoli. NPM also involved in the maturation of preribosomes and duplication of centrosomes. Furthermore, it is also active in control and regulation of the ARF-p53 tumor suppressor pathway. A high rate of incidence and prognostic involvement is reported by various authors in AML patients. In AML it behaves as a favorable prognostic marker. NPM mutations are more frequently associated with normal-karyotype AML and are usually absent in patients having abnormal or poor cytogenetic. NPM mutations are not frequent in other hematopoietic tumors. Two main types of mutations have been described to date. Both of these cause abnormal cytoplasmic localization of NPM1. Their high incidence rate in normal karyoptype and their favorable nature m ake those mutations hot spot or front face mutations which should be checked before treatment starts.
Keywords
Nucleophosmin; prognostic marker; AML; normal karyotype; NPM mutations; exon 12;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Suzuki T, Kiyoi H, Ozeki K, et al (2005). Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood, 106, 2854-61.   DOI   ScienceOn
2 Tan A, Westerman DA, Carney DA, et al. (2008) Detection of NPM1 exon 12 mutations and FLT3 - internal tandem duplications by high resolution melting analysis in normal karyotype acute myeloid leukemia. J Hematol Oncol, 1, 10.   DOI   ScienceOn
3 Taussig DC, Vargaftig J, Miraki-Moud F, et al (2010). Leukemia initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34fraction. Blood, 115, 1976-84.   DOI   ScienceOn
4 Thiede C, Creutzig E, Reinhardt D, Ehninger G, Creutzig U (2007). Different types of NPM1 mutations in children and adults: evidence for an effect of patient age on the prevalence of the TCTG-tandem duplication in NPM1-exon 12. Leukemia, 21, 366-7.   DOI   ScienceOn
5 Thiede C, Koch S, Creutzig E, et al (2006). Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood, 107, 4011-20.   DOI   ScienceOn
6 Thiede C, Steudel C, Mohr B, et al (2002). Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99, 4326-35.   DOI   ScienceOn
7 Verhaak RG, Goudswaard CS, van P W, et al (2005). Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood, 106, 3747-54.   DOI   ScienceOn
8 Wu MH, Chang JH, Yung BY (2002). Resistance to UV-induced cellkilling in nucleophosmin/B23 overexpressed NIH 3T3 fibroblasts: enhancement of DNA repair and up-regulation of PCNA in association with nucleophosmin/B23 overexpression. Carcinogenesis, 23, 93-100.   DOI   ScienceOn
9 Albiero E, Madeo D, Giaretta I, et al (2006). A novel mutation in the exon 11 of nucleophosmin (NPM1) gene leads to a truncated form of the protein lacking the C-terminal NES-motif. Haematologica, 91, 237.
10 Ahmad F, Mandava S, Das BR (2009). Mutations of NPM1 gene in de novo acute myeloid leukaemia: determination of incidence, distribution pattern and identification of two novel mutations in Indian population. Hematol Oncol, 27, 90-7.   DOI   ScienceOn
11 Ammatuna E, Noguera NI, Zangrilli D, et al (2005). Rapid detection of nucleophosmin (NPM1) mutations in acute myeloid leukemia by denaturing HPLC. Clin Chem, 51, 2165-7.   DOI   ScienceOn
12 Becker H, Marcucci G, Maharry K, et al (2010). Favorable prognostic impactof NPM1 mutations in older patients withcytogenetically normal de novo acute myeloidleukemia and associated gene- and microRNA-expression signatures: a cancer andleukemia group B study. J Clin Oncol, 28, 596-604.   DOI   ScienceOn
13 Bertwistle D, Sugimoto M, Sherr CJ (2004). Physical and functional interactions of the ARF tumor suppressor protein with nucleophosmin/B23. Mol Cell Biol, 24, 985-96.   DOI   ScienceOn
14 Boonthimat C, Thongnoppakhun W, Auewarakul CU (2008). Nucleophosmin mutation in Aoutheast Asian acute myeloid leukemia: eight novel variants, FLT3 coexistence and prognostic impact of NPM1/FLT3 mutations. Haematologica, 93, 1565-9.   DOI   ScienceOn
15 Boissel N, Renneville A, Biggio V, et al (2005). Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood, 106, 3618-20.   DOI   ScienceOn
16 Cazzaniga G, Dell'Oro MG, Mecucci C, et al (2005). Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood, 106, 1419-22.   DOI   ScienceOn
17 Bolli N, Nicoletti I, De Marco MF, et al (2007). Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants. Cancer Res, 67, 6230-7.   DOI   ScienceOn
18 Bonetti P, Davoli T, Sironi C, et al (2008). Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7 gamma. J Cell Biol, 182, 19-26.   DOI   ScienceOn
19 Brown P, McIntyre E, Rau R, et al (2007). The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood, 110, 979-85.   DOI   ScienceOn
20 Chang JH, Olson MO (1990). Structure of the gene for rat nucleolar protein B23. J Biol Chem, 265, 18227-33.
21 Chou WC, Tang JL, Lin LI, et al (2006). Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. Cancer Res, 66, 3310-6.   DOI   ScienceOn
22 Dalia N, Mohammed AR, Dominique B (2011). Incidence and prognostic value of NPM1 and FLT3 gene mutations in AML with normal karyotype. Open J Hematol, 5, 14-20.   DOI
23 Colombo E, Bonetti P, Lazzerini Denchi E, et al (2005). Nucleophosmin is required for DNA integrity and p19ARF protein stability. Mol Cell Biol, 25, 8874-86.   DOI   ScienceOn
24 Colombo E, Martinelli P, Zamponi R, et al (2006). Delocalization and destabilization of the ARF tumor suppressor by the leukemia-associated NPM mutant. Cancer Res, 66, 3044-50.   DOI   ScienceOn
25 Falini B, Bolli N, Shan J, et al (2006). Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMcp AML. Blood, 107, 4514-23.   DOI   ScienceOn
26 den Besten W, Kuo ML, Williams RT, Sherr CJ (2005). Myeloid leukemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the ARF tumor suppressor protein. Cell Cycle, 4, 1593-8.   DOI
27 Dohner K, Schlenk RF, Habdank M, et al (2005). Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood, 106, 3740-6.   DOI   ScienceOn
28 Falini B, Bolli N, Liso A, et al (2009). Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia, 23, 1731-43.   DOI   ScienceOn
29 Falini B, Mecucci C, Tiacci E, et al (2005). Cytoplasmic nucleophosmin in acute myelogenous leukemia with abnormal karyotype. N Engl J Med, 352, 254-66.   DOI   ScienceOn
30 Gorello P, Cazzaniga G, Alberti F, et al (2006). Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia, 20, 1103-8.   DOI   ScienceOn
31 Falini B, Nicoletti I, Bolli N, et al (2007). Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica, 92, 519-32.   DOI
32 Falini B, Martelli MP, Bolli N (2011). Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood, 117, 1109-20.   DOI   ScienceOn
33 Herrera JE, Correia JJ, Jones AE, Olson MO (1996). Sedimentation analyses of the salt- and divalent metal ion induced oligomerization of nucleolarprotein B23. Biochemistry, 35, 2668-73.   DOI   ScienceOn
34 Gjerset RA, Bandyopadhyay K (2006). Regulation ofp14ARF through subnuclear compartmentalization. Cell Cycle, 5, 686-90.   DOI
35 Grisendi S, Bernardi R, Rossi M, et al (2005). Role of nucleophosmin in embryonic development and tumorigenesis. Nature, 437, 147-53.   DOI   ScienceOn
36 Hafez M, Ye F, Jackson K, et al (2010). Performance and clinical evaluation of a sensitive multiplex assay for the rapid detection of common NPM1 mutations. J Mol Diagn, 12, 629-35.   DOI   ScienceOn
37 Hingorani K, Szebeni A, Olson MO (2000). Mapping the functional domains of nucleolar protein B23. J Biol Chem, 275, 24451-7.   DOI   ScienceOn
38 Huang Q, Chen W, Gaal KK, et al (2008). A rapid, one step assay for simultaneous detection of FLT3/ITDand NPM1 mutations in AML with normal cytogenetics. Br J Haematol, 142, 480-501.   DOI   ScienceOn
39 Kim YK, Kim HN, Lee SR, et al (2010). Prognostic significance of nucleophosmin mutations and FLT3 internal tandem duplication in adult patients with cytogenetically normal acute myeloid leukemia. Korean J Hematol, 45, 36-45.   DOI   ScienceOn
40 Jeon Y, Seo SW, Park S, et al (2013). Identification of two novel NPM1 mutations in patients with acute myeloid leukemia. Ann Lab Med, 33, 60-4.   DOI   ScienceOn
41 Kazem AH, Mikhael IL, Ghanem AM (2011). Cytoplasmic nucleophosmin (cNPM) in acute myeloid leukaemia: Relation to disease characteristics. AJM, 47, 225-35.
42 Kuzmanovic M, Tosic N, Colovic N, et al (2012). Mutations in Serbian adult patients with acute myeloid leukemia. Acta Haematol, 128, 203-12.   DOI   ScienceOn
43 Krstovski N, Tosic N, Janic D, et al (2010). Incidence of FLT3 and nucleophosmin genemutations in childhood acute myeloid leukemia: Serbian experience and the review of the literature. Med Oncol, 27, 640-5.   DOI   ScienceOn
44 Kurki S, Peltonen K, Latonen L, et al (2004). Nucleolarprotein NPM interacts with HDM2 and protectstumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell, 5, 465-75.   DOI   ScienceOn
45 Kuo ML, den Besten W, Bertwistle D, Roussel MF, Sherr CJ (2004). N-terminal polyubiquitination and degradation of the ARF tumor suppressor. Genes Dev, 18, 1862-74.   DOI   ScienceOn
46 Laughlin TS, Becker MW, Liesveld JL, et al (2008). Rapid method for detection of mutations in the nucleophosmin gene in acute myeloid leukemia. J Molecular Diag, 10, 338-45.   DOI   ScienceOn
47 Luo J, Qi C, Xu W, et al (2010). Cytoplasmic expression of nucleophosmin accurately predicts mutation in the nucleophosmin gene in patients with acute myeloid leukemia and normal karyotype. Am J Clin Pathol, 133, 34-40.   DOI   ScienceOn
48 Lee SY, Park JH, Kim S, et al (2005). A proteomics approach for the identification of nucleophosmin and heterogeneous nuclear ribonucleoprotein C1/C2 as chromatin- binding proteins in response to DNA double-strand breaks. Biochem J, 388, 7-15.   DOI   ScienceOn
49 Li J, Sejas DP, Rani R, et al (2006). Nucleophosmin regulates cell cycle progression and stress response in hematopoietic stem/progenitor cells. J Biol Chem, 281, 16536-45.   DOI   ScienceOn
50 Lin Ll, Lin TC, Chou WC, et al (2006). A novel fluorescencebased multiplex PCR assay for rapid simultaneous detection of CEBPA mutations and NPM mutations in patients with acute myeloid leukemias. Leukemia, 20, 1899-903.   DOI   ScienceOn
51 Mariano AR, Colombo E, Luzi L, et al (2006). Cytoplasmic localization of NPM in myeloid leukemias is a functional nuclear export signal. Oncogene, 25, 4376-80.   DOI   ScienceOn
52 Mattsson G, Turner SH, Cordell J, et al (2010). Can cytoplasmic nucleophosmin be detected by immunocytochemical staining of cell smears in acute myeloid leukemia? Haematologica, 95, 670-3.   DOI
53 Mori Y, Yoshimoto G, Kumano T, et al (2007). Distinctive expression of myelomonocytic markers and down-regulation of CD34 in acute myelogenous leukaemia with FLT3 tandem duplication and nucleophosmin mutation. Eur J Hematol, 79, 17-24.   DOI   ScienceOn
54 Oppliger Leibundgut E, Porret NA, Bienz Muggli M, et al (2012). Rapid and highly specific screening for NPM1 mutations in acute myeloid leukemia. Ann Hematol, 92, 173-7.
55 Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD (2007). Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood, 109, 431-48.   DOI   ScienceOn
56 Mullighan CG, Kennedy A, Zhou X, et al (2007). Pediatric acute myeloid leukemia with NPM1 mutations ischaracterised by a gene expression profile with dysregulatedHOX gene expression distinct from MLL-rearranged leukemias. Leukemia, 21, 2000-9.   DOI   ScienceOn
57 Roti G, Rosati R, Bonasso R, et al (2006). Denaturing high-performance liquid chromatography: a valid approach for identifying NPM1 mutations in acute myeloid leukemia. J Mol Diagn, 8, 254-9.   DOI   ScienceOn
58 Okuwaki M, Matsumoto K, Tsujimoto M, Nagata K (2001). Function of nucleophosmin/B23, a nucleolar acidic protein, as a histone chaperone. FEBS Lett, 506, 272-6.   DOI   ScienceOn
59 Ottone T, Ammatuna E, Lavorgna S (2008). An allele-specific rt-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia. J Mol Diagn, 10, 212-6.   DOI   ScienceOn
60 Palmisano M, Grafone T, Ottaviani E, et al (2007). NPM1 mutations are more stable than FLT3mutations during the course of disease in patients with acute myeloid leukemia. Haematologica, 92, 1268-9.   DOI
61 Ruan GR, Li JL, Qin YZ, et al (2008). Nucleophosmin mutations in Chinese adults with acute myelogenous leukemia. Ann Hematol, 88, 159-66..
62 Schneider F, Hoster E, Schneider S, et al (2012). Age-dependent frequencies of NPM1 mutationsand FLT3-ITD in patients with normal karyotype AML (NK-AML). Ann Hematol, 91, 9-18.   DOI   ScienceOn
63 Szankasi P, Jama M, Bahler DW (2008). A new DNA-based test for detection of nucleophosmin exon 12 mutations by capillary electrophoresis. J Mol Diagn, 10, 236-41.   DOI   ScienceOn
64 Schnittger S, Schoch C, Kern W, et al (2005). Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood, 106, 3733-9.   DOI   ScienceOn
65 Micol JB, Boissel N, Renneville A, (2009) et al. The role of cytogenetic abnormalities in acute myeloid leukemia with NPM1 mutations and no FLT3 internal tandem duplication. Blood, 114, 4601-2.   DOI   ScienceOn
66 Braoudaki M, Chrissa P, Katerina K, et al (2010). The frequency of NPM1 mutations in childhood acute myeloid leukemia. J Hematol Oncol, 3, 41.   DOI   ScienceOn
67 Haferlach C, Mecucci C, Schnittger S, et al (2009). AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood, 114, 3024-32.   DOI   ScienceOn
68 Shimada A, Taki T, Kubota C, et al (2007). Nonucleophosmin mutations in pediatric acute myeloid leukemiawith normal karyotype: a study of the Japanese childhood AML cooperative study group. Leukemia, 21, 1307.   DOI   ScienceOn
69 Colombo E, Marine JC, Danovi D, Falini B, Pelicci PG (2002). Nucleophosmin regulates the stability andtranscriptional activity of p53. Nat Cell Biol, 4, 529-33.   DOI   ScienceOn
70 Kassem N, Hamid AA, Attia T, et al (2011). Novel mutations of the nucleophosmin (NPM-1) gene in Egyptian patients with acute myeloid leukemia: a pilot study. J Egypt Natl Cancer Inst, 23, 73-8.   DOI   ScienceOn